BioTeZ Berlin-Buch GmbH of Berlin at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers Service OEM

BioTeZ Berlin-Buch GmbH

Robert-Rössle-Str. 10, 13125 Berlin
Germany
Telephone +49 30 94892130
Fax +49 30 9494509
info@biotez.de

This company is co-exhibitor of
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.

Hall map

MEDICA 2018 hall map (Hall 3): stand G54

Fairground map

MEDICA 2018 fairground map: Hall 3

Contact

Dr. Janko Brand

Uwe Ahnert

Visit us

Hall 3 / G54

12.11.2018

Topic

all-day

Tutorial and Demonstration of the Therapeutic Drug Monitoring recoveryELISA

Therapeutic Drug Monitoring (TDM) solutions: The patented recoveryELISA technology allows multi-parameter measurements supporting dose finding, pharmacokinetic and pharmacodynamics studies leading to personalized medicine and diagnostic approaches. The recoveryELISA is established for PCSK9 and Evolocumab; Adalimumab/Infliximab and TNFa as well as Omalizumab and IgE. A customization for your biological and antigen can be discussed on site.

More Less

13.11.2018

Topic

all-day

Tutorial and Demonstration of the Therapeutic Drug Monitoring recoveryELISA

Therapeutic Drug Monitoring (TDM) solutions: The patented recoveryELISA technology allows multi-parameter measurements supporting dose finding, pharmacokinetic and pharmacodynamics studies leading to personalized medicine and diagnostic approaches. The recoveryELISA is established for PCSK9 and Evolocumab; Adalimumab/Infliximab and TNFa as well as Omalizumab and IgE. A customization for your biological and antigen can be discussed on site.

More Less

14.11.2018

Topic

all-day

Tutorial and Demonstration of the Therapeutic Drug Monitoring recoveryELISA

Therapeutic Drug Monitoring (TDM) solutions: The patented recoveryELISA technology allows multi-parameter measurements supporting dose finding, pharmacokinetic and pharmacodynamics studies leading to personalized medicine and diagnostic approaches. The recoveryELISA is established for PCSK9 and Evolocumab; Adalimumab/Infliximab and TNFa as well as Omalizumab and IgE. A customization for your biological and antigen can be discussed on site.

More Less

15.11.2018

Topic

all-day

Tutorial and Demonstration of the Therapeutic Drug Monitoring recoveryELISA

Therapeutic Drug Monitoring (TDM) solutions: The patented recoveryELISA technology allows multi-parameter measurements supporting dose finding, pharmacokinetic and pharmacodynamics studies leading to personalized medicine and diagnostic approaches. The recoveryELISA is established for PCSK9 and Evolocumab; Adalimumab/Infliximab and TNFa as well as Omalizumab and IgE. A customization for your biological and antigen can be discussed on site.

More Less

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.01  Clinical chemistry
  • 03.01.04  Rapid tests in clinical chemistry
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.04  Other equipment for immunochemistry and immunology

Our products

Product category: Immuno assay testing

Mass spectrometry: LC-MS/MS dilute and shoot versus IAC-LC-MS/MS

For many users of the tandem mass spectrometry the “dilute and shoot “technique appears as a simple method to solve interference problems with sample matrix. Increasing sensitivities of new generations of mass spectrometers seem to confirm this view. However, in the case of residue analysis with high quantitative accuracy, matrix effects due to ion suppression are disturbing and even the entire MS / MS system suffers in the long because of the high level of contamination for the introduced matrix.

Help can be provided by clean up columns, such as the multitoxin IAC B-TeZ IAC Combi AOZDFT 3ml optimized for the mycotoxin analysis, for the specific accumulation of afla- and ochratoxins, zearalenone, DON, fumonisin, T2 and HT2 toxin.

Before the samples reach the mass spectrometer almost all matrix constituents can be separated by the clean-up columns and thus often represent a clear improvement to the solid phase extraction columns. This procedure protects the mass spectrometer, saves maintenance and is stable due to the reduction of the matrix effect so the use of stable-isotopically labeled reference standards can be avoided.

In addition to the classic 3 ml single analyte clean-up column, BioTeZ also offers multi analyt clean-up columns. On request BioTeZ develops pressure-resistant guard columns for online or permanent operation, for example for vitamin B12 analysis, folic acid or biotin, as well as individual immunoaffinity columns for various autosamplers in sample preparation.

More Less

Product category: Rapid tests in clinical chemistry

Successful partnering for fast diagnostic tools in neurodegenerative diseases and heart failure

BioTeZ and the German Heart Institute Berlin developed a unique and reliable
diagnostics tool box to quantify the RNA-Binding Motif Protein 3 (RBM3) in patient
samples. The results of this successful cooperation lead to a highly specific ELISA
and lateral flow quick test.
It is known that the expression of RBM3 is upregulated upon cold shock
(hypothermia) (Dresios et al., 2005). The therapeutic benefit a cold shock has been
known for 60 years (Arrica & Bissonnette, 2007), and therapeutic hypothermia serves
as a method in cardiac surgeries in new born children to lower the risk of organ
damage as well as oxygen loss during birth (perinatale asphyxie) (Shankaran et al.,
2005).
In adults hypothermia is a standard of care for patients suffering from heart attacks
(Bernard et al., 2002) and the therapeutic benefits for ischemia/reperfusion and
traumatic brain injuries are currently under investigation (Groysman et al., 2011).
Since the treatment indications for hypothermia are increasing, so will the demand by
enlarged clinical studies to employ the evaluation of RBM3 as a possible biomarker.
“With this lateral flow test it now possible to quickly quantify the RBM3 level in the
patient’s blood. With this important information the physician can plan more precisely
the treatment”, says Uwe Ahnert, CEO at BioTeZ GmbH.
Furthermore, it was recently shown that RBM3 is involved in hypothermia induced
neuroprotection (Chip et al., 2011) and a protective effect of the RBM3 in
neurodegenerative disorders was demonstrated (Peretti et al., 2015). The now
available RBM3-ELISA technology will support researcher in the field of Alzheimer,
dementia, Parkinson, stroke, autoimmunity, depression, and neuronal hyperactivity.
“We are delighted to hold this RBM3 ELISA-kit in hand, which will allow the
evaluation of this important biomarker in patients to prevent neurodegenerative
disorders” says Dr. MD Katharina Schmitt from the German Heart Institute
(Deutsches Herzzentrum Berlin).

More Less

Product category: Diagnostic rapid tests

Diagnostic method allows adjustment of drug dose in rheumatoid arthritis patients

New diagnostic method allows adjustment of drug dose in
rheumatoid arthritis patients

Collaboration between the Immanuel Klinikum Bernau Herzzentrum Brandenburg, the
Rheumazentrum Nord-Brandenburg and BioTeZ demonstrates new ways of treating
rheumatoid arthritis. The results of the joint study are published in the current issue of the
journal "Clinical and Experimental Rheumatology".
Through the introduction of therapeutic antibodies, the treatment results for rheumatoid arthritis (RA)
have been significantly improved over the past decade. However, cases of inadequate effectiveness
remain, as well as side effects due to the associated strong immunosuppression, especially with high
activity levels. One possibility for therapy optimization is the targeted, individual dose adjustment of the
active ingredients for each patient. At the moment, all RA patients treated with the TNF-alpha inhibitor
adulimumab received a pre-approved standard dose of 40 mg every 14 days without regard for existing
differences in body weight, sex, health status, metabolism and age. As a result, some patients receive too
high drug dose and other patients have too low drug levels.
Using the test (recoveryELISA from BioTeZ), it is now possible simultaneously quantify the concentrations
of the therapeutic antibody adalimumab and the target antigen TNF alpha in the patient's serum during
therapy (Zänker et al., 2017). The Figure 1 summarizes the results of the study, with the patients being
divided into three groups.
Figure 1: Graphical summary of the results
A total 47% of the patients showed drug levels in the target area, leading to an effective neutralization of
TNF-alpha. 35% of the patients showed low drug doses resulting in reduced TNF alpha neutralization
rates under standard therapy. 18% of patients had increased drug levels and high neutralization rates. A
further dose increase for these patients is not useful is not recommended.
"If the effect of the drug is insufficient and the drug level is low, a dose increase of the adalimumab by a
weekly injection can lead to a significantly better therapeutic response (Zänker et al., 2017). This is in line
with our everyday experience in the clinics and has now been scientifically documented in this study",
says Dr. Michael Zänker, rheumatologist and chief physician for internal medicine at Immanuel Klinikum
Bernau Herzzentrum Brandenburg.
In the case of very high drug levels, as in 18% of the patients and if the therapeutic goal is achieved,
there is the possibility of de-escalating the therapy, by stretching the interval of the injections by serval
days. Thus the amount of active substance in the patient can be reduced to the recommended values,
while avoiding possible side effects as well as reducing treatment costs.
"The results contribute to the individual treatment of patients with rheumatoid arthritis and are an
important add on to the therapy prediction of anti-TNF-alpha monotherapy with adalimumab" so, Dr.
Janko Brand, scientific director of the study at BioTeZ

More Less

Product category: Other equipment for immunochemistry and immunology

BioTeZ Streptavidin Reagents & Services Polystrept R: for highest binding on Lateral Flow Stripes

The streptavidin-biotin system offers a universal immobilization principle for the detection and analysis of proteins, peptides, PCR fragments and other biomolecules. Streptavidin Coating is a convenient method for uniform and stable immobilization of biotinylated molecules in a directed way while avoiding or minimizing denaturation.

BioTeZ Custom Coating Service
BioTeZ has long standing experience in the field of Streptavidin coating based on own patented
procedures, which allow us to coat any type of material such as various plastics, membranes, metal, glass and others. We routinely coat plastics such as Polystyrene, Polyethylene, Polypropylene, Polycarbonate, Poly(methyl methacrylate) PMMA or Polyamides. Our technique guarantees a high homogeneity and ensures a high reproducibility in your experiments. On request we coat any type of microplate. Choose the optimal microplate material for your experiment!

Polystrept R - Coating Reagent
Polystrept R is a macromolecule with excellent adsorption properties and extraordinary high Biotin binding capacity. Coatings made of Polystrept R combine the excellent binding capacity with a high chemo and thermo stability. Would you like to perform your own streptavidin coatings? BioTeZ has designed the Polystrept R Coating Solution - very suitable for coating membranes, biochips, plastics etc. Improve your Lateral Flow Tests by using Polystrept R. Sensational effects already in low concentration:
■ Better signals
■ Low noise
■ Cost savings

More Less

Product category: Immuno assay testing, Other equipment for immunochemistry and immunology

Novel therapeutic drug monitoring assay for Evolocumab and PCSK9

The first PCSK9 Inhibitors reach the market and BioTeZ just completed the development project for the therapeutic drug and antigen monitoring assay. The recoveryELISA® (RPE) allows the simultaneous quantification of the free PCSK9 and the free Evolocumab in one ELISA assay.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has medical importance since it directly interferes with the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. Agents which block PCSK9 can decrease the LDL particle concentrations in the blood and thereby prevent cardiovascular disease.

The first therapeutic monoclonal antibodies against PCSK9 Evolocumab and Alirocumab were approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

For Evolocumab two different dosing regimes are suggested 140 mg every two weeks or 420 mg once per month. By definition Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimes (1).

“The recoveryELISA® RPE is the only method that simultaneously quantifies the free PCSK9, the PCSK9 neutralization rate and the free available therapeutic antibody Evolocumab in human serum samples during Evolocumab therapy. With our new recoveryELISA® RPE we support TDM studies and can contribute for a truly personalized dose finding strategy” explains Uwe Ahnert (CEO of BioTeZ).

A pilot study enrolled Evolocumab naïve patients suffering from residual cardiovascular disease, treated for the first time with evolocumab and followed for the next two injections. Serum samples were tested with the recoveryELISA© RPE to quantify free PCSK9 and free evolocumab simultaneously and compared these results with the lipid profile.

“We are glad to demonstrate the ability of the recoveryELISA© PCSK9 & Evolocumab for this important application in a clinical setting. Currently, we evaluate the data and we will start soon with writing up a publication on our findings” says Dr. Janko Brand (senior Scientist at BioTeZ).

Product specifications: The working range for PCSK9 is 0.04 - 0.35 µg/mL and Evolocumab 0.2- 24.0 µg/mL. Please use the serum samples at dilution of 1:10. Keep in mind that BioTeZ has also totalPCSK9 ELISA® (BTPCSK9-001) on stock for the quantification of PCSK9.

More Less

About us

Company details

We are your partner for Immunochemistry Solutions & Assay Manufacturer! We are experts in Assay Development/ Validation (various formats) and also OEM Manufacturer for individual Kit Components/ Coatings/ Conjugates (Poly-HRP, Europium etc.)/ Customized Microplates; Immobilization Systems: unique Tags/ Streptavidin/ high capacity Polystrept for Quick Test Membranes or other surfaces; ELISA; Therapeutic Drug Monitoring Biologics: Evolocumab/PCSK9 (Cardio Vascular ), Omalizumab/IgE (Allergy), Adalimumab/TNFa (Rheumatism); We Customiz Gels & Columns for Affinity Chromatography: Mycotoxin/Vitamin Clean-up Columns; DNA/RNA Primer Synthesis incl. Modifications; Drug Discovery: Human Proteases/ Enzymes/ Proteins; Enzyme Activity Assays; Parkinson Diagnostics: COMT, MAO-B, DDC & Inhibitors

More Less

Company data

Sales volume

1-9 Mio US $

Export content

max. 75%

Number of employees

20-49

Foundation

1992

Area of business
  • Laboratory Equipment
  • Diagnostics

Company information as a PDF file